{'52WeekChange': -0.34679985,
 'SandP52WeekChange': None,
 'address1': 'Building No. 2',
 'address2': '10222 Barnes Canyon Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.02,
 'askSize': 800,
 'averageDailyVolume10Day': 127812,
 'averageVolume': 218969,
 'averageVolume10days': 127812,
 'beta': 1.271985,
 'beta3Year': None,
 'bid': 13.97,
 'bidSize': 800,
 'bookValue': 4.41,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.77,
 'dayLow': 13.78,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.822,
 'enterpriseToRevenue': 393.639,
 'enterpriseValue': 353093920,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 16.699715,
 'fiftyTwoWeekHigh': 26.67,
 'fiftyTwoWeekLow': 10.63,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 17380234,
 'forwardEps': -2.67,
 'forwardPE': -5.2509365,
 'fromCurrency': None,
 'fullTimeEmployees': 68,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.044910002,
 'heldPercentInstitutions': 0.747,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/crinetics.com',
 'longBusinessSummary': 'Crinetics Pharmaceuticals, Inc., a clinical stage '
                        'pharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of therapeutics '
                        'for rare endocrine diseases and endocrine-related '
                        'tumors. Its lead product candidate is paltusotine, an '
                        'oral selective nonpeptide somatostatin receptor type '
                        '2 biased agonist, which is in Phase I clinical trials '
                        'used for the treatment of acromegaly and '
                        'neuroendocrine tumors. The company is also developing '
                        'CRN01941, an oral selective nonpeptide sst2 biased '
                        'agonist designed for the treatment of neuroendocrine '
                        'tumors; an oral selective nonpeptide somatostatin '
                        'type 5 receptor agonist for treating congenital '
                        'hyperinsulinism; and an oral adrenocorticotrophic '
                        "hormone antagonist for the treatment of cushing's and "
                        'congenital adrenal hyperplasia diseases. Crinetics '
                        'Pharmaceuticals, Inc. was founded in 2008 and is '
                        'headquartered in San Diego, California.',
 'longName': 'Crinetics Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 460495328,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_280584191',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -58766000,
 'nextFiscalYearEnd': 1640908800,
 'open': 14.77,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 450 6464',
 'previousClose': 14.39,
 'priceHint': 2,
 'priceToBook': 3.1791384,
 'priceToSalesTrailing12Months': 513.37274,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.77,
 'regularMarketDayLow': 13.78,
 'regularMarketOpen': 14.77,
 'regularMarketPreviousClose': 14.39,
 'regularMarketPrice': 14.77,
 'regularMarketVolume': 127411,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 32845600,
 'sharesPercentSharesOut': 0.077199996,
 'sharesShort': 2537079,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1384774,
 'shortName': 'Crinetics Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.106000006,
 'shortRatio': 6.84,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CRNX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.421,
 'twoHundredDayAverage': 18.217627,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '8657b861-d8f0-3350-943c-fa486f0f26d0',
 'volume': 127411,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.crinetics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}